Targovax AS logo

Targovax AS

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target solid tumors. Targovax AS is a clinical stage biotech company develops active immunotherapy in the form of cancer vaccines.

Targovax was established in 2010 by inventors of the technology and The Radium Hospital Research Foundation.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.targovax.com
Founded2010
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
Vollsveien 6, 1366
Lysaker
Norway
Email
Contact Number
+47 213 98 810

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/targovax-as” connections=”true” suffix=””]

Targovaxs technology is cancer cell specific, and educates the patients immune system to recognize and kill cancer cells. Targovax peptides are designed for induction of RAS mutation specific T-helper cells through presentation on HLA class II molecules on the surface of Antigen Presenting Cells (APCs), but also for natural processing to potential HLA class I epitopes and induction of RAS mutation specific cytotoxic T cells.

In June 2015, Targovax acquired Oncos Therapeutics Oy in an all-stock transaction.

Key investors include Birk Venture, Radium Hospital Research Foundation and RO Invest.